Supplementary table 1. Prognostic Impact of *MYB* Expression on Survival in the PrognoScan Database*

Dataset	Endpoint	Cohort / Contributor	Array Type	Probe ID	No. of Patients	Cut-point	Minimum P Value	Corrected P Value	ln(HRhigh/HRlow)	Cox P Value	ln(HR)	HR (95% CI)
GSE17536	Disease Specific Survival	MCC/Smith	HG-U133_Plus_2	204798_at	177	0.15	0.011848	0.183288	-0.77	0.005184	-0.40	0.67 [0.50 - 0.89]
GSE17536	Overall Survival	MCC/Smith	HG-U133_Plus_2	215152_at	177	0.54	0.008905	0.147911	-0.63	0.026171	-1.03	0.36 [0.14 - 0.89]
GSE17536	Overall Survival	MCC/Smith	HG-U133_Plus_2	204798_at	177	0.10	0.022432	0.290409	-0.72	0.025300	-0.30	0.74 [0.56 - 0.96]
GSE17536	Disease Free Survival	MCC/Smith	HG-U133_Plus_2	204798_at	145	0.37	0.017053	0.239186	-0.78	0.033815	-0.49	0.61 [0.39 - 0.96]
GSE17536	Disease Specific Survival	MCC/Smith	HG-U133_Plus_2	215152_at	177	0.41	0.000362	0.010753	-0.95	0.011368	-1.40	0.25 [0.08 - 0.73]
GSE17537	Overall Survival	VMC/Smith	HG-U133_Plus_2	204798_at	55	0.13	0.000713	0.019166	-1.52	0.075207	-0.41	0.67 [0.43 - 1.04]
GSE17537	Overall Survival	VMC/Smith	HG-U133_Plus_2	215152_at	55	0.53	0.002251	0.049903	-1.55	0.065410	-1.94	0.14 [0.02 - 1.13]
GSE14333	Disease Free Survival	Melbourne/ Jorissen	HG-U133_Plus_2	215152_at	226	0.19	0.000157	0.005213	-1.05	0.121368	-0.19	0.83 [0.65 - 1.05]
GSE14333	Disease Free Survival	Melbourne/ Jorissen	HG-U133_Plus_2	204798_at	226	0.12	0.000017	0.000727	-1.30	0.000269	-0.67	0.51 [0.36 - 0.73]

HR indicates hazard ratio; CI, confidence interval;
*Studies were identified in a search performed July 19, 2018.

Supplementary table 2. Prognostic Impact of *MYB* Expression on Survival in the SurvExpress Database*

Dataset	Endpoint	Cohort / Contributor	No. of Patients	Concordance Index	Log−Rank Equal Curves P value	HR (95% CI)	Beta	Cox P value (Beta)	P value (DEG)
COADREAD	Survival	TCGA Colon and Rectum adenocarcinoma	466	0.61	0.0485	1.5 (1-2.25)	−1.057	0.00086217	3.55e−66
GSE14333	Disease Free Survival	Jorissen Sieber	226	0.6	0.0356	1.83 (1.03-3.24)	−0.668	0.00026784	4.83e−45
GSE17536	Survival	Smith Beauchamp	177	0.57	0.0474	1.59 (1-2.53)	−0.340	0.01197088	1.58e−30
Colon−Metabase−Uniformized	Disease Free Survival		545	0.57	0.1635	1.28 (0.9-1.83)	−3.705	0.00000137	3.62e−40
GSE24551	Recurrence	Sveen−Agesen	189	0.59	0.4633	1.22 (0.72-2.07)	−0.428	0.00126840	5.17e−30
GSE41258	Survival	Sheffer−Domany	243	0.57	0.2215	1.28 (0.86-1.9)	−0.315	0.00023933	3.21e−35
Colon Rectal Adenocarcinoma	Survival	TCGA	151	0.67	0.0277	3.09 (1.07-8.96)	−0.474	0.04887556	3.82e−25
GSE12945	Survival	Staub	62	0.66	0.1193	2.52 (0.76-8.38)	−1.208	0.04786045	5.85e−13

HR indicates hazard ratio; CI, confidence interval; Beta, β-coefficient; DEG, differentially expressed gene
*Studies were identified in a search performed July 9, 2018.